Related Experiment Video
Updated: Dec 12, 2025
14:46
Dendrimer-based Uneven Nanopatterns to Locally Control Surface Adhesiveness: A Method to Direct Chondrogenic Differentiation
Published on: January 20, 2018
8.1K
Dendrimers toward Translational Nanotherapeutics: Concise Key Step Analysis
Serge Mignani1,2,3, Xiangyang Shi2,4, João Rodrigues2,5
1Université Paris Descartes, PRES Sorbonne Paris Cité, CNRS UMR 860, Laboratoire de Chimie et de Biochimie Pharmacologiques et Toxicologique, 45, rue des Saints Peres, 75006 Paris, France.
Bioconjugate Chemistry
|August 14, 2020
Summary
This review discusses developing druggable nanoparticles, particularly dendrimers, for nanomedicine. It outlines criteria for nanoparticle development and the preclinical to commercialization roadmap for clinical translation.
Area of Science:
- Nanomedicine
- Biotechnology
- Materials Science
Background:
- Nanomedicine aims to revolutionize healthcare with precise diagnostic and therapeutic tools.
- Nanomolecular structures, including dendrimers and polymers, show promise as nanocarriers, therapeutics, and imaging agents.
Purpose of the Study:
- To review criteria for developing druggable nanoparticles, focusing on dendrimers.
- To outline the preclinical and clinical roadmap for nanoparticle commercialization.
Main Methods:
- Literature review of nanomedicine research.
- Analysis of nanoparticle engineering and functionalization.
- Discussion of preclinical and clinical development pathways.
Main Results:
- Dendrimers and polymers possess significant potential as versatile nanocarriers and agents.
- Key parameters for creating therapeutically viable nanoparticles are identified.
- The stages from preclinical development to market commercialization are detailed.
Conclusions:
- Successful clinical translation of nanomedicine requires careful consideration of development criteria and regulatory pathways.
- Dendrimer-based nanomedicines offer a promising avenue for addressing clinical challenges.
